Gilead Sciences, Inc.
American biopharmaceutical company headquartered in Foster City, California; researches and develops antiviral drugs for HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, plus oncology, inflammation, and cell therapy medicines.
Clinical Trials
696
673 active
Approvals
55
Total approvals
Agencies
2
Regulatory bodies
Founded
1987
Active, not recruiting
670
96.3%
Completed
9
1.3%
Not yet recruiting
3
0.4%
Recruiting
8
1.1%
Terminated
2
0.3%
Unknown
4
0.6%
- Nurix Therapeutics is advancing NX-5948, an oral BTK degrader, in Phase 2 trials for relapsed/refractory B-cell malignancies and autoimmune diseases. - NX-2127, another oral BTK degrader, is being evaluated in Phase 1a/1b trials for relapsed or refractory B-cell malignancies. - The company is also developing NX-1607, an oral CBL-B inhibitor in Phase 1a/1b trials for immuno-oncology indications, and NX-0479/GS-6791, an IRAK4 degrader for rheumatoid arthritis. - Nurix holds strategic collaborations with Gilead Sciences, Sanofi, and Pfizer for co-development and co-commercialization of multiple drug candidates.
- Gilead Sciences and Kymera Therapeutics have entered into an exclusive option and license agreement to develop novel molecular glue degraders targeting CDK2 for cancer treatment. - The collaboration focuses on CDK2-directed molecular glue degraders that selectively remove the CDK2 protein from cells rather than just inhibiting its function, potentially offering more precise cancer treatments. - Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments, plus tiered royalties on net product sales. - The oral CDK2 degraders have demonstrated compelling preclinical profiles and target breast cancer and other solid tumors with high unmet medical need.
- The U.S. gene therapy market is expected to grow from $4.37 billion in 2025 to $22.23 billion by 2034, driven by increasing investments, rising prevalence of chronic diseases, and integration of advanced technologies. - Gene silencing has emerged as the dominant segment in the market, while oncology applications currently lead but neurology treatments are anticipated to gain significant market share in the coming decade. - Artificial intelligence is revolutionizing gene therapy development by analyzing genomic data, identifying therapeutic targets, enabling personalized treatment strategies, and optimizing manufacturing processes to reduce costs.
- A recent study highlights that single viral load tests may produce false positive HIV results in individuals using long-acting injectable cabotegravir (CAB-LA) PrEP. - Confirmatory testing with a second blood sample effectively distinguishes true positives from false positives, ensuring accurate HIV detection in PrEP users. - False positives can lead to unnecessary PrEP interruptions and psychological distress, emphasizing the need for optimized HIV testing algorithms. - Antibody-based tests combined with viral load tests show promise in improving the accuracy of HIV detection among individuals on CAB-LA PrEP.
- Long-acting injectable cabotegravir (CAB-LA) is shown to be safe and well-tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy. - The study monitored over 300 pregnancies and infants, revealing similar adverse outcomes across groups using CAB-LA, prior CAB-LA use, or no CAB-LA use. - These findings support CAB-LA as a viable HIV prevention option for cisgender women before, during, and after pregnancy, addressing a critical need. - The research highlights the importance of diverse PrEP options for women, particularly in regions with high HIV incidence and specific pregnancy-related risks.
